In vitro studies conducted with tissue samples and cancer cell lines have shown that SEC62 is overexpressed in tumors relative to tumor-free tissue at the protein and mRNA levels in lung, prostate, head and neck, and cervical cancers [14,15,16,17]. This evidence concerns the gene SEC62 and cancer.